Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase IIa/IIb randomized multicenter study of orelabrutinib in adults with persistent or chronic primary immune thrombocytopenia
CTR20213348Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in immune thrombocytopenia (ITP), sponsored by Innovent Biologics. Started Feb 2022; status: active.
02
Drugs
orelabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20213348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213348.